Also, in the pre-clinical trials, Kevetrin was tested by itself. Given that Kevetrin's MOA is different from that of all currently approved cancer drugs, it's highly likely that, in phase 2 trials, Kevetrin will be administered in conjunction with currently approved cancer meds, thereby increasing the likelihood of positive results even further.
A1